GB201208309D0 - Complexes - Google Patents

Complexes

Info

Publication number
GB201208309D0
GB201208309D0 GB201208309A GB201208309A GB201208309D0 GB 201208309 D0 GB201208309 D0 GB 201208309D0 GB 201208309 A GB201208309 A GB 201208309A GB 201208309 A GB201208309 A GB 201208309A GB 201208309 D0 GB201208309 D0 GB 201208309D0
Authority
GB
United Kingdom
Prior art keywords
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201208309A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AS
Original Assignee
Algeta ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Algeta ASA filed Critical Algeta ASA
Priority to GB201208309A priority Critical patent/GB201208309D0/en
Publication of GB201208309D0 publication Critical patent/GB201208309D0/en
Priority to EP13721784.0A priority patent/EP2846842A1/en
Priority to HK15107608.2A priority patent/HK1206981A1/xx
Priority to CA2873142A priority patent/CA2873142A1/en
Priority to US14/400,020 priority patent/US20150104385A1/en
Priority to JP2015510839A priority patent/JP2015523326A/ja
Priority to CN201380035189.1A priority patent/CN104602716A/zh
Priority to US14/400,026 priority patent/US9827336B2/en
Priority to KR1020147034743A priority patent/KR20150092702A/ko
Priority to US14/400,031 priority patent/US20150147272A1/en
Priority to CA2873144A priority patent/CA2873144C/en
Priority to JP2015510838A priority patent/JP6211066B2/ja
Priority to JP2015510840A priority patent/JP6219372B2/ja
Priority to HK15108017.5A priority patent/HK1207307A1/xx
Priority to CN201380036807.4A priority patent/CN104619355A/zh
Priority to PCT/EP2013/059839 priority patent/WO2013167754A1/en
Priority to KR1020147034741A priority patent/KR20150092700A/ko
Priority to EP13725586.5A priority patent/EP2846844B1/en
Priority to CA 2873143 priority patent/CA2873143A1/en
Priority to CN201380036905.8A priority patent/CN104540530A/zh
Priority to HK15107609.1A priority patent/HK1206982A1/xx
Priority to PCT/EP2013/059841 priority patent/WO2013167756A1/en
Priority to PCT/EP2013/059840 priority patent/WO2013167755A1/en
Priority to EP13721975.4A priority patent/EP2846843A1/en
Priority to KR1020147034742A priority patent/KR20150092701A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
GB201208309A 2012-05-11 2012-05-11 Complexes Ceased GB201208309D0 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
GB201208309A GB201208309D0 (en) 2012-05-11 2012-05-11 Complexes
KR1020147034742A KR20150092701A (ko) 2012-05-11 2013-05-13 방사성―약제 복합체
JP2015510840A JP6219372B2 (ja) 2012-05-11 2013-05-13 放射性医薬錯体
CN201380036807.4A CN104619355A (zh) 2012-05-11 2013-05-13 放射性药物络合物
CA2873142A CA2873142A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
US14/400,020 US20150104385A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
JP2015510839A JP2015523326A (ja) 2012-05-11 2013-05-13 放射性医薬錯体
CN201380035189.1A CN104602716A (zh) 2012-05-11 2013-05-13 放射性药物络合物
US14/400,026 US9827336B2 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
KR1020147034743A KR20150092702A (ko) 2012-05-11 2013-05-13 방사성 제약 복합체
US14/400,031 US20150147272A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
CA2873144A CA2873144C (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
JP2015510838A JP6211066B2 (ja) 2012-05-11 2013-05-13 放射性医薬錯体
EP13721784.0A EP2846842A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
HK15108017.5A HK1207307A1 (zh) 2012-05-11 2013-05-13 放射性药物络合物
HK15107608.2A HK1206981A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
PCT/EP2013/059839 WO2013167754A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
KR1020147034741A KR20150092700A (ko) 2012-05-11 2013-05-13 방사성―약제 복합체
EP13725586.5A EP2846844B1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
CA 2873143 CA2873143A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
CN201380036905.8A CN104540530A (zh) 2012-05-11 2013-05-13 放射性药物络合物
HK15107609.1A HK1206982A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
PCT/EP2013/059841 WO2013167756A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
PCT/EP2013/059840 WO2013167755A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes
EP13721975.4A EP2846843A1 (en) 2012-05-11 2013-05-13 Radio-pharmaceutical complexes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201208309A GB201208309D0 (en) 2012-05-11 2012-05-11 Complexes

Publications (1)

Publication Number Publication Date
GB201208309D0 true GB201208309D0 (en) 2012-06-27

Family

ID=46458687

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201208309A Ceased GB201208309D0 (en) 2012-05-11 2012-05-11 Complexes

Country Status (9)

Country Link
US (3) US9827336B2 (https=)
EP (3) EP2846842A1 (https=)
JP (3) JP6211066B2 (https=)
KR (3) KR20150092702A (https=)
CN (3) CN104619355A (https=)
CA (3) CA2873144C (https=)
GB (1) GB201208309D0 (https=)
HK (3) HK1206982A1 (https=)
WO (3) WO2013167754A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2511266B1 (en) 2006-07-10 2019-09-04 The Regents of The University of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
EP2816038B8 (en) 2009-08-24 2019-12-25 Lumiphore, Inc. Hopo chelators
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
MA41176A (fr) * 2014-12-17 2017-10-24 Bayer As Complexes radio-pharmaceutiques
US10821195B2 (en) * 2015-09-10 2020-11-03 Memorial Sloan Kettering Cancer Center Compositions for therapeutics, targeted PET imaging and methods of their use
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
PE20190168A1 (es) * 2016-03-24 2019-02-01 Bayer Pharma AG Complejos radiofarmaceuticos
WO2017211809A1 (en) 2016-06-10 2017-12-14 Bayer Pharma Aktiengesellschaft Radio-pharmaceutical complexes
EP3585436A1 (en) 2017-02-24 2020-01-01 Bayer AS Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
CN111918877A (zh) * 2018-03-14 2020-11-10 美国卫生和人力服务部 抗cd33嵌合抗原受体及其用途
EP3843743A1 (en) 2018-08-28 2021-07-07 Bayer AS Combination of pi3k-inhibitors and targeted thorium conjugates
US11279698B2 (en) * 2018-11-20 2022-03-22 Cornell University Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
USD885822S1 (en) 2018-12-14 2020-06-02 Whirlpool Corporation Food grinder
CA3130747A1 (en) 2019-02-21 2020-08-27 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
CA3130809A1 (en) 2019-02-22 2020-08-27 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
EP4003959A1 (en) 2019-07-25 2022-06-01 Bayer AS Targeted radiopharmaceuticals for the diagnosis and treatment of prostate cancer
BR112022013678A2 (pt) * 2020-01-10 2022-11-16 Fusion Pharmaceuticals Inc Quelatos macrocíclicos e seus usos
AU2020424030B2 (en) * 2020-01-23 2025-05-29 Radtran Llc Systems and methods for preparing tailored radioactive isotope solutions
US20240000838A1 (en) * 2020-11-30 2024-01-04 Simcere Innovation, Inc. Universal chimeric antigen receptor-expressing immune cells for allogeneic cell therapy
AU2022210371A1 (en) 2021-01-22 2023-07-20 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
AU2024339683A1 (en) 2023-09-13 2026-03-26 Toray Industries, Inc. Pharmaceutical composition for treating, preventing and/or diagnosing cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
US5624901A (en) 1994-04-15 1997-04-29 The Regents Of The University Of California 3-hydroxy-2(1H)-pyridinone chelating agents
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
NO312708B1 (no) 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
NO313180B1 (no) 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0308731D0 (en) 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
EP2497501B1 (en) * 2004-06-25 2019-05-01 The European Union, represented by the European Commission Radionuclides for medical use
US7794691B2 (en) * 2004-06-25 2010-09-14 The European Community, Represented By The European Commission Radionuclides for medical use
WO2008063721A2 (en) 2006-08-15 2008-05-29 The Regents Of The University Of California Luminescent macrocyclic lanthanide complexes
US8158804B2 (en) 2007-01-11 2012-04-17 Ge Healthcare As Chelating agents
CA2768658C (en) * 2009-07-22 2018-04-03 Actinium Pharmaceuticals, Inc. Methods for generating radioimmunoconjugates
WO2011079291A1 (en) * 2009-12-24 2011-06-30 Lumiphore, Inc. Radiopharmaceutical complexes
EP2359802B1 (en) * 2010-02-12 2014-06-18 Evonik Degussa GmbH Cosmetic composition containing polyglycerol partial ester
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) 2012-05-11 2012-06-27 Algeta As Complexes

Also Published As

Publication number Publication date
KR20150092702A (ko) 2015-08-13
CN104619355A (zh) 2015-05-13
US9827336B2 (en) 2017-11-28
WO2013167756A1 (en) 2013-11-14
US20150147272A1 (en) 2015-05-28
JP2015523326A (ja) 2015-08-13
WO2013167755A1 (en) 2013-11-14
CA2873143A1 (en) 2013-11-14
KR20150092700A (ko) 2015-08-13
US20150104385A1 (en) 2015-04-16
JP6219372B2 (ja) 2017-10-25
CN104540530A (zh) 2015-04-22
CA2873144A1 (en) 2013-11-14
HK1207307A1 (zh) 2016-01-29
US20150110817A1 (en) 2015-04-23
HK1206981A1 (en) 2016-01-22
JP2015517482A (ja) 2015-06-22
CA2873144C (en) 2021-03-16
EP2846842A1 (en) 2015-03-18
EP2846844A1 (en) 2015-03-18
KR20150092701A (ko) 2015-08-13
CN104602716A (zh) 2015-05-06
CA2873142A1 (en) 2013-11-14
EP2846844B1 (en) 2020-04-01
HK1206982A1 (en) 2016-01-22
JP6211066B2 (ja) 2017-10-11
WO2013167754A1 (en) 2013-11-14
JP2015517483A (ja) 2015-06-22
EP2846843A1 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
IL254716A0 (en) Zinc-lysine conjugate
GB201208309D0 (en) Complexes
DK2830816T3 (en) Hidtil ukendt coatingkoncept
DK3327112T3 (en) Agse-deficient stamme
EP2935220A4 (en) PERI-carbinol
EP2920142A4 (en) MÉTHANOFULLERRÈNES
EP2928915A4 (en) FGF-10 COMPLEX
GB201203307D0 (en) Remvox
GB201104522D0 (en) Complexes
GB201214746D0 (en) Biomolecular complexes
GB201210358D0 (en) Complexes
GB2499853B (en) MicBooth
GB201214016D0 (en) Concept 36a
AU345893S (en) Treehouse
GB201208402D0 (en) Globaldrum
GB201203777D0 (en) Quit-clip
GB201203776D0 (en) Sili-m8
GB201203815D0 (en) Mini-meals
GB201203612D0 (en) Ishopfront
GB201203604D0 (en) Envelope-box
GB201203507D0 (en) Keynut
GB201203440D0 (en) Blu-seals
GB201203453D0 (en) TVtidy
GB201203045D0 (en) Chrismar
GB201202916D0 (en) E-Space

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)